570 related articles for article (PubMed ID: 26413868)
21. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
22. Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells.
Heinkelein M; Sopper S; Jassoy C
J Virol; 1995 Nov; 69(11):6925-31. PubMed ID: 7474110
[TBL] [Abstract][Full Text] [Related]
23. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals.
Ahmad A; Morisset R; Thomas R; Menezes J
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):428-37. PubMed ID: 7908983
[TBL] [Abstract][Full Text] [Related]
24. Primary cytotoxicity against the envelope glycoprotein of human immunodeficiency virus-1: evidence for antibody-dependent cellular cytotoxicity in vivo.
Tanneau F; McChesney M; Lopez O; Sansonetti P; Montagnier L; Rivière Y
J Infect Dis; 1990 Oct; 162(4):837-43. PubMed ID: 1698205
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
[TBL] [Abstract][Full Text] [Related]
26. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
[TBL] [Abstract][Full Text] [Related]
27. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure.
Kent SJ; Greenberg PD; Hoffman MC; Akridge RE; McElrath MJ
J Immunol; 1997 Jan; 158(2):807-15. PubMed ID: 8992998
[TBL] [Abstract][Full Text] [Related]
28. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
29. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
30. Killing of Latently HIV-Infected CD4 T Cells by Autologous CD8 T Cells Is Modulated by Nef.
Sevilya Z; Chorin E; Gal-Garber O; Zelinger E; Turner D; Avidor B; Berke G; Hassin D
Front Immunol; 2018; 9():2068. PubMed ID: 30254642
[TBL] [Abstract][Full Text] [Related]
31. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
32. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
Emini EA; Koff WC
Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
[No Abstract] [Full Text] [Related]
33. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
[TBL] [Abstract][Full Text] [Related]
34. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
35. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
[TBL] [Abstract][Full Text] [Related]
36. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
Ferrari G; Pollara J; Tomaras GD; Haynes BF
J Infect Dis; 2017 Mar; 215(suppl_3):S152-S159. PubMed ID: 28520963
[TBL] [Abstract][Full Text] [Related]
37. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
[TBL] [Abstract][Full Text] [Related]
38. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
[TBL] [Abstract][Full Text] [Related]
39. Elimination of latently HIV-1-infected cells by lymphoblasts armed with bifunctional antibody.
Yin S; Okada N; Okada H
Microbiol Immunol; 2001; 45(1):101-8. PubMed ID: 11270601
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
